Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right

```
                    Truncation
NEWS 38  AUG 18  Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
              MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:00:20 ON 11 SEP 2003

=> file medline, uspatful, dgene, embase, wpids
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 11:00:32 ON 11 SEP 2003

FILE 'USPATFULL' ENTERED AT 11:00:32 ON 11 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:00:32 ON 11 SEP 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 11:00:32 ON 11 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'WPIDS' ENTERED AT 11:00:32 ON 11 SEP 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s Flash compound
L1            10 FLASH COMPOUND

=> d l1 ti abs ibib tot

L1   ANSWER 1 OF 10  USPATFULL on STN
TI     Cyclic amine compounds as CCR5 antagonists
AB     A compound of formula (I) (wherein R.sup.1 is a hydrogen atom, a
       hydrocarbon group which may be substituted, a non-aromatic heterocyclic
       group which may be substituted, R.sup.2 is a hydrocarbon group which may
       be substituted, a non-aromatic heterocyclic group which may be
       substituted, or R.sup.1 and R.sup.2 may combine to each other together
       with A to form a heterocyclic group which may be substituted; A is N or
       N.sup.+--R.sup.5.Y.sup.- (R.sup.5 is a hydrocarbon group; Y.sup.- is a
       counter anion); R.sup.3 is a cyclic hydrocarbon group which may be
       substituted or a heterocyclic group which may be substituted; n is 0 or
       1; R.sup.4 is a hydrogen atom, a hydrocarbon group which may be
       substituted, a heterocyclic group which may be substituted, an alkoxy
       group which may be substituted, an aryloxy group which may be
       substituted, or an amino group which may be substituted, E is a divalent
```

aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G.sup.1 is a bond, CO or SO.sub.2; G.sup.2 is CO, SO.sub.2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C.sub.1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G.sub.2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G.sup.1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:166585 USPATFULL
TITLE: Cyclic amine compounds as CCR5 antagonists
INVENTOR(S): Imamura, Shinichi, Osaka, JAPAN
Hashiguchi, Shohei, Osaka, JAPAN
Hattori, Taeko, Osaka, JAPAN
Nishimura, Osamu, Kawanishi-shi, JAPAN
Kanzaki, Naoyuki, Osaka, JAPAN
Baba, Masanori, Kagoshima-shi, JAPAN
Sugihara, Yoshihiro, Ikoma-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114443	A1	20030619
APPLICATION INFO.:	US 2002-273111	A1	20021018 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-89374, filed on 29 Mar 2002, PENDING A 371 of International Ser. No. WO 2000-JP6755, filed on 29 Sep 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-282088	19991001
	JP 2000-46749	20000218

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
LINE COUNT: 18451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 10 USPATFULL on STN
TI Cartridge format delay igniter
AB A training device for simulating the action of stun grenades and the like is provided by combining a delay cartridge with a conversion fitting that installs in a grenade body. A firing assembly fitted to the grenade body over the delay cartridge is percussively initiated through release of a hammer to activate a primer located on the end of the cartridge. The cartridge contains a delay-burning compound that subsequently activates a pyrotechnic charge. A suitable application is for training in the use of flash/bang training devices or "stun" grenades.

ACCESSION NUMBER: 2002:282218 USPATFULL
TITLE: Cartridge format delay igniter
INVENTOR(S): Murray, Kenneth R., 3516 Furlong Way, Gotha, FL, United States 34734

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6470806	B1	20021029
APPLICATION INFO.:	US 2000-514258		20000228 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jordan, Charles T.
ASSISTANT EXAMINER: Semunegus, Lulit
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 370

L1 ANSWER 3 OF 10 USPATFULL on STN
TI Image information in color reversal materials using weak and strong inhibitors
AB An improved color reversal element is disclosed capable of development in black and white developer, and of development in a color developer comprising:

a support having thereon at least two light-sensitive silver halide emulsion layers and a combination of compounds (A) and (B)

Compound (A) capable of releasing a development modifier having the structural formula

M(Time).sub.n --INH(1)

wherein

M is a carrier, moiety from which --(Time).sub.n --INH(1) is released during black and white development to provide a weak inhibitor;

Compound (B) having the structural formula

CAR--(TIME).sub.n --INH(2)

wherein:

CAR is a carrier moiety from which --(TIME).sub.n --INH(2) is released during color development to provide a strong inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 95:3751 USPATFULL
TITLE: Image information in color reversal materials using weak and strong inhibitors
INVENTOR(S): Harder, John W., Rochester, NY, United States
Baloga, John D., Rochester, NY, United States
PATENT ASSIGNEE(S): Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5380633		19950110	
APPLICATION INFO.:	US 1993-5319		19930115	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bowers, Jr., Charles L.
ASSISTANT EXAMINER: Letscher, Geraldine
LEGAL REPRESENTATIVE: Stewart, Gordon M.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 2176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 10 USPATFULL on STN
TI Aminoalcohol intermediates for peptide derivatives
AB The invention concerns pharmaceutically useful trifluoromethyl ketone

substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	93:20683 USPATFULL
TITLE:	Aminoalcohol intermediates for peptide derivatives
INVENTOR(S):	Edwards, Philip D., Claymont, DE, United States Schwartz, John A., Wilmington, DE, United States Stein, Mark M., Wilmington, DE, United States Trainor, Diane A., Glen Mills, PA, United States Wildonger, Richard A., Newark, DE, United States
PATENT ASSIGNEE(S):	ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5194588		19930316	
APPLICATION INFO.:	US 1990-491757		19900309	(7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-1522	19850122
	GB 1985-1523	19850122
	GB 1985-1524	19850122

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Lee, Lester L.
LEGAL REPRESENTATIVE:	Miano, Rosemary M., Jackson, Thomas E.
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
LINE COUNT:	5515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 10 USPATFULL on STN

TI Alkoxysilane cluster compounds and their preparation

AB Novel alkoxysilane cluster compounds are described having the formula RSi[Osi(OR').sub.3].sub.3 wherein R is hydrogen, an alkyl, alkenyl, aryl or aralkyl group and each R' is independently selected from the same group as R with the proviso that at least a majority of R' radicals are sterically hindered alkyl groups having at least 3 carbon atoms. The preparation of these novel alkoxysilane cluster compounds is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	76:35053 USPATFULL
TITLE:	Alkoxysilane cluster compounds and their preparation
INVENTOR(S):	Knollmueller, Karl O., Hamden, CT, United States
PATENT ASSIGNEE(S):	Olin Corporation, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 3965136		19760622	
APPLICATION INFO.:	US 1975-616438		19750924	(5)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Shaver, Paul F.			

LEGAL REPRESENTATIVE: Glynn, Kenneth P.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 10 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilised on a solid support -
AN AAM48100 peptide DGENE
AB The invention relates to a method of isolating a polypeptide of interest comprising contacting a modified Fluorescein arsenical helix binder (**FlAsH**) **compound** immobilised on a solid support with a solution containing modified polypeptide, to contain a FlAsH target sequence motif, under conditions to allow binding of polypeptide to immobilised **FlAsH compound** and eluting the polypeptide from immobilised **FlAsH compound**. The method is useful for isolating a polypeptide of interest from a cell lysate, crude polypeptide extract, partially purified polypeptide extract, a cell or cell free solution derived from plant, prokaryote or an eukaryote. The method yields substantially pure protein from a single purification step. The specific reaction between modified bis-arsenical molecule and target sequence is reversible and the complex containing the modified bis-arsenical molecule and target sequence can be dissociated. Protein purification using the immobilised **FlAsH compound** can be adapted for use in many different types of chromatography.
ACCESSION NUMBER: AAM48100 peptide DGENE
TITLE: Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilised on a solid support -
INVENTOR: Vale R D; Thorn K; Cooke R; Matuska M; Naber N
PATENT ASSIGNEE: (REGC)UNIV CALIFORNIA.
PATENT INFO: WO 2001053325 A2 20010726 52p
APPLICATION INFO: WO 2001-US2214 20010122
PRIORITY INFO: US 2000-178054P 20000124
US 2000-502664 20000211
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602285 [68]
DESCRIPTION: Fluorescein arsenical helix peptide.

L1 ANSWER 7 OF 10 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilised on a solid support -
AN AAM48099 peptide DGENE
AB The invention relates to a method of isolating a polypeptide of interest comprising contacting a modified Fluorescein arsenical helix binder (**FlAsH**) **compound** immobilised on a solid support with a solution containing modified polypeptide, to contain a FlAsH target sequence motif, under conditions to allow binding of polypeptide to immobilised **FlAsH compound** and eluting the polypeptide from immobilised **FlAsH compound**. The method is useful for isolating a polypeptide of interest from a cell lysate, crude polypeptide extract, partially purified polypeptide extract, a cell or cell free solution derived from plant, prokaryote or an eukaryote. The method yields substantially pure protein from a single purification step. The specific reaction between modified bis-arsenical molecule and target sequence is reversible and the complex containing the modified bis-arsenical molecule and target sequence can be dissociated. Protein purification using the immobilised **FlAsH**

compound can be adapted for use in many different types of chromatography.

ACCESSION NUMBER: AAM48099 peptide DGENE
TITLE: Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilised on a solid support -
INVENTOR: Vale R D; Thorn K; Cooke R; Matuska M; Naber N
PATENT ASSIGNEE: (REGC)UNIV CALIFORNIA.
PATENT INFO: WO 2001053325 A2 20010726 52p
APPLICATION INFO: WO 2001-US2214 20010122
PRIORITY INFO: US 2000-178054P 20000124
US 2000-502664 20000211
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602285 [68]
DESCRIPTION: Fluorescein arsenical helix binder target sequence motif.

L1 ANSWER 8 OF 10 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilized on a solid support.
AN 2001-602285 [68] WPIDS
AB WO 200153325 A UPAB: 20011121
NOVELTY - A method of isolating (M) a polypeptide of interest comprises contacting a modified Fluorescein arsenical helix binder (**FlAsH**) **compound** immobilized on a solid support with a solution containing modified polypeptide, to contain a FlAsH target sequence motif, under conditions to allow binding of polypeptide to immobilized **FlAsH compound**, and eluting the polypeptide from immobilized **FlAsH compound**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a DNA construct (DC) comprising an origin of replication, a selectable marker, a promoter that allows expression of the polypeptide and a multiple cloning site, where at the 5' or 3' end of the multiple cloning site is a genetically-encoded affinity tag or is a FlAsH target sequence motif;

(2) a method for producing a polypeptide of interest which has at its N-terminus a genetically-encoded affinity tag and at its C-terminus a FlAsH target sequence motif comprises:

(i) expressing a DNA sequence which encodes the polypeptide of interest from DC in a cell and producing the polypeptide of interest from the cells;

(ii) contacting a solution comprising (a) polypeptide with an affinity resin binding to the affinity tag, (b) eluting polypeptides to affinity column, (c) contacting the modified FIAsH compounds immobilized on a solid support with polypeptides from (b) under conditions that allow binding of polypeptide to FIAsH compound, and (d) eluting the polypeptide from immobilized FIAsH compound; or

(iii) contacting a solution comprising (a) polypeptide with a FIAsH compound immobilized to a solid support, (b) eluting polypeptides to immobilized FIAsH compound, (c) contacting an affinity resin with the polypeptide solution from (b) under conditions that allow binding of polypeptide to the affinity resin, and (d) eluting the polypeptide from affinity resin; or

(3) a kit comprising a modified **FlAsH compound** immobilized on a solid support; and

(4) a modified FlAsH of formula (I), its tautomers, anhydrides or salts, where R is the product of an acylation reaction using any amino acid.

USE - (M) is useful for isolating a polypeptide of interest from a cell lysate, crude polypeptide extract, partially purified polypeptide extract, a cell or cell free solution derived from plant, prokaryote or an eukaryote (claimed).

ADVANTAGE - The method yields substantially pure protein from a single purification step. The specific reaction between modified bis-arsenical molecule and target sequence is reversible and the complex containing the modified bis-arsenical molecule and target sequence can be dissociated. Protein purification using the immobilized **FlAsH compound** can be adapted for use in many different types of chromatography.

Dwg.0/1

ACCESSION NUMBER: 2001-602285 [68] WPIDS
DOC. NO. CPI: C2001-178345
TITLE: Isolating polypeptide of interest from cell lysate or crude polypeptide extract, by using a modified Fluorescein arsenical helix binder compound immobilized on a solid support.
DERWENT CLASS: A89 B04 D16 E12 E23
INVENTOR(S): COOKE, R; MATUSKA, M; NABER, N; THORN, K; VALE, R D
PATENT ASSIGNEE(S): (REGC) UNIV CALIFORNIA
COUNTRY COUNT: 22

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001053325	A2	20010726	(200168)*	EN	52
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR					
W: AU CA JP					
AU 2001031086	A	20010731	(200171)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001053325	A2	WO 2001-US2214	20010122
AU 2001031086	A	AU 2001-31086	20010122

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001031086	A Based on	WO 2001053325

PRIORITY APPLN. INFO: US 2000-502664 20000211; US 2000-178054P 20000124

L1 ANSWER 9 OF 10 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Flash photolysis apparatus for microscopic imaging of flash-photolysized compounds in specimens.
AN 1999-457727 [38] WPIDS
AB US 5936728 A UPAB: 19990922

NOVELTY - The flash photolysis apparatus (10) has a target detector (15) that receives the scanning beam (12) passing through an aperture (27) from an optical path (26). The target detector output signal is correlated with the scanning beam to determine the position at which the scanning beam passes through on a specimen (46), and the position at which the excitation beam (21) is incident on the specimen.

DETAILED DESCRIPTION - A pulse illumination source (20) outputs the excitation beam which has light pulses of selected wavelength to provide photolysis. An excitation coupler (23) receives the excitation beam from the pulse illumination source and directs the excitation beam to the optical path. The optical path, which consists of optical transmission elements and is included in the main coupler, directs the excitation beam from the excitation coupler to a dichroic mirror beam splitter. The dichroic mirror beam splitter directs the excitation beam to the optics of a microscope (13) focussed onto the specimen. The dichroic mirror beam splitter also receives the scanning beam from a scanning system (11) to

direct it to the microscope, and directs the scanning beam back on the optical path to the excitation coupler through the aperture.

An INDEPENDENT CLAIM is included for the flash photolysis method.

USE - For microscopic imaging of flash-photolysized compounds in specimens, in which a scanning beam is produced to illuminate the specimen. Used in biology and microscopy.

ADVANTAGE - Can be used with full image capture microscope system as well as scanning systems. Operates flash photolysis while maintaining continuous and superimposed imaging of the target area to which the flash is directed. Can be readily interfaced to a laser scanning imaging system. Allows three-dimensional localization of flash-photolysized areas and visualization of photolysis effects. Ensures continuous imaging of target area during targeting, application of flash excitation beam and subsequent emissions from the target. Ensures continuous live imaging of entire area under inspection with minimal modification on existing scanning imaging systems or whole field imaging systems.

DESCRIPTION OF DRAWING(S) - The figure shows the schematic view of the flash photolysis apparatus incorporated with a laser scanning system and an optical microscope.

Flash photolysis apparatus 10
Scanning system 11
Scanning beam 12
Microscope 13
Target detector 15
Pulse illumination source 20
Excitation beam 21
Excitation coupler 23
Optical path 26
Aperture 27
Specimen 46
Dwg.2/5

ACCESSION NUMBER: 1999-457727 [38] WPIDS
DOC. NO. NON-CPI: N1999-342372
TITLE: Flash photolysis apparatus for microscopic imaging of flash-photolysized compounds in specimens.
DERWENT CLASS: S02 S03
INVENTOR(S): BOUZID, A
PATENT ASSIGNEE(S): (NORA-N) NORAN INSTR INC
COUNTRY COUNT: 3
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 5936728	A	19990810	(199938)*		12
GB 2336498	A	19991020	(199945)		
DE 19916773	A1	19991021	(199950)		
GB 2336498	B	20021218	(200307)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5936728	A	US 1998-60008	19980414
GB 2336498	A	GB 1999-8051	19990408
DE 19916773	A1	DE 1999-19916773	19990414
GB 2336498	B	GB 1999-8051	19990408

PRIORITY APPLN. INFO: US 1998-60008 19980414

L1 ANSWER 10 OF 10 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Lighting or flashing compound light source module - directs input signal to AND to obtain bias current and turns LED on of off NoAbstract Dwg 1/4.
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

ACCESSION NUMBER: 1992-109563 [14] WPIDS
TITLE: Lighting or flashing compound light source module - directs input signal to AND to obtain bias current and turns LED on of off NoAbstract Dwg 1/4.
DERWENT CLASS: P85 T04 U12
PATENT ASSIGNEE(S): (NIDE) NEC CORP
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 04051283	A	19920219	(199214)*		3

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 04051283	A	JP 1990-161620	19900620

PRIORITY APPLN. INFO: JP 1990-161620 19900620

=> s fluorescein arsenical helix binder compound or FlAsH
L2 189641 FLUORESCEIN ARSENICAL HELIX BINDER COMPOUND OR FLASH

=> s l2 and acylation
L3 4962 L2 AND ACYLATION

=> s l3 and beta alanine
L4 303 L3 AND BETA ALANINE

=> s l4 and tautomer
L5 11 L4 AND TAUTOMER

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 11 USPATFULL on STN
TI N-alkyl-adamantyl triazinyl benzamide derivatives
AB The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I ##STR1##

and to processs for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the treatment of inflammation, osteoarthritis, rhematoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:207932 USPATFULL
TITLE: N-alkyl-adamantyl triazinyl benzamide derivatives
INVENTOR(S): Duplantier, Allen J., Ledyard, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144293	A1	20030731	
APPLICATION INFO.:	US 2002-292886	A1	20021112	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-336892P	20011112	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 11 USPATFULL on STN
TI Electrophilic ketones for the treatment of herpesvirus infections
AB A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II ##STR1##

wherein each of R.sup.1, R.sup.2, and R.sup.3 is independently selected from hydrido, halo, and nitro; wherein R.sup.8 is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; wherein Y is selected from fluoroalkyl, and ##STR2##

wherein R.sup.9 is alkylamino; or a pharmaceutically-acceptable salt or **tautomer** thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:173873 USPATFULL
TITLE: Electrophilic ketones for the treatment of herpesvirus infections
INVENTOR(S): Flynn, Daniel L., Clarkson Valley, MO, UNITED STATES
Zablocki, Jeffery, Lafayette, CO, UNITED STATES
Williams, Kenneth, Evanston, IL, UNITED STATES
Hockerman, Susan L., Chicago, IL, UNITED STATES
PATENT ASSIGNEE(S): G. D. Searle & Co., Corporate Patent Department, Chicago, IL (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119721	A1	20030626
APPLICATION INFO.:	US 2002-303596	A1	20021125 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-712002, filed on 14 Nov 2000, PENDING Continuation of Ser. No. US 1998-221016, filed on 23 Dec 1998, ABANDONED Continuation of Ser. No. US 1996-620681, filed on 19 Mar 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Corporate Patent Department, 800 North Lindbergh, Mail Zone O4E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 2118
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 11 USPATFULL on STN
TI Novel triazolo-pyridines anti-inflammatory compounds
AB The present invention relates to novel triazolo-pyridines of the formula I ##STR1##

wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen;

R.sup.2 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

s is an integer from 0-5;

to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:140996 USPATFULL
TITLE: Novel triazolo-pyridines anti-inflammatory compounds
INVENTOR(S): McClure, Kim F., Mystic, CT, UNITED STATES
Letavic, Michael A., Mystic, CT, UNITED STATES
Dombroski, Mark A., Waterford, CT, UNITED STATES
Duplantier, Allen J., Ledyard, CT, UNITED STATES
Laird, Ellen R., Longmont, CO, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096838	A1	20030522	
APPLICATION INFO.:	US 2002-94760	A1	20020311	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-274840P	20010309	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 5372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 11 USPATFULL on STN
TI Substituted pyrimidinone and pyridone compounds and methods of use
AB Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:175161 USPATFULL
TITLE: Substituted pyrimidinone and pyridone compounds and methods of use
INVENTOR(S): Spohr, Ulrike D., Boulder, CO, United States
Malone, Michael J., Boulder, CO, United States
Mantlo, Nathan B., Lafayette, CO, United States
Zablocki, Jeffery A., Lafayette, CO, United States
PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 6420385	B1	20020716
APPLICATION INFO.:	US 2000-504509		20000215 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-985346, filed on 4 Dec 1997, now patented, Pat. No. US 6096753 Continuation-in-part of Ser. No. US 1997-976053, filed on 21 Nov 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32128P	19961205 (60)
	US 1997-50950P	19970613 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Ungemach, Frank S., Watt, Stuart L.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 7407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 11 USPATFULL on STN
TI Integrin antagonists
AB This invention relates to novel heterocycles which are useful as antagonists of the .alpha..sub.v.beta..sub.3 integrin, the .alpha..sub.2b.beta..sub.3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:212538 USPATFULL
TITLE: Integrin antagonists
INVENTOR(S): Pitts, William J., Newtown, PA, United States
Jadhav, Prabhakar K., Wilmington, DE, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001044535	A1	20011122
	US 6489333	B2	20021203
APPLICATION INFO.:	US 2001-828751	A1	20010409 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-282496, filed on 31 Mar 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1999-US6827	19990329
	US 1998-80242P	19980401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dupont Pharmaceuticals Company, Legal Department - Patents, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 7881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 11 USPATFULL on STN

TI Substituted pyrimidinone and pyridone compounds and methods of use
AB Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:98438 USPATFULL
TITLE:	Substituted pyrimidinone and pyridone compounds and methods of use
INVENTOR(S):	Spohr, Ulrike D., Boulder, CO, United States Malone, Michael J., Boulder, CO, United States Mantlo, Nathan B., Lafayette, CO, United States
PATENT ASSIGNEE(S):	Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096753		20000801
APPLICATION INFO.:	US 1997-985346		19971204 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-976053, filed on 21 Nov 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32128P	19961205 (60)
	US 1997-50950P	19970613 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Coleman, Brenda
LEGAL REPRESENTATIVE:	Odre, Steven, Levy, Ron, Ungemach, Frank
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
LINE COUNT:	7725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 11 USPATFULL on STN
TI N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe- and phenethylamine derivatives
AB Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:42906 USPATFULL
TITLE:	N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe- and phenethylamine

derivatives

INVENTOR(S): Horwell, David C., Foxton, England
Pritchard, Martyn C., Swavesey, England
Roberts, Edward, Wood Ditton, England
Richardson, Reginald S., Haverhill, England
Aranda, Julian, Vorstetter, Germany, Federal Republic of

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5631281		19970520
APPLICATION INFO.:	US 1994-235814		19940428 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-958196, filed on 7 Oct 1992, now abandoned which is a division of Ser. No. US 1990-629809, filed on 19 Dec 1990, now patented, Pat. No. US 5278316 which is a continuation-in-part of Ser. No. US 1990-545222, filed on 28 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-580811, filed on 5 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-422486, filed on 16 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-374327, filed on 29 Jun 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 5726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 11 USPATFULL on STN

TI N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe- and phenethylamine derivatives

AB Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:33778 USPATFULL
TITLE: N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe- and phenethylamine derivatives
INVENTOR(S): Horwell, David C., Foxton, England
Pritchard, Martyn C., Swavesey, England
Roberts, Edward, Wood Ditton, England
Richardson, Reginald S., Haverhill, England
Aranda, Julian, Vorstetter, Germany, Federal Republic of

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5622983		19970422
APPLICATION INFO.:	US 1995-447141		19950522 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-235814, filed on 28 Apr 1994 which is a continuation-in-part of Ser. No. US 1992-958196, filed on 7 Oct 1992, now abandoned which is a division of Ser. No. US 1990-629809, filed on 19 Dec 1990, now patented, Pat. No. US 5278316 which is a continuation-in-part of Ser. No. US 1990-545222, filed on 28 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-530811, filed on 5 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-422486, filed on 16 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-374327, filed on 29 Jun 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 5641
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 11 USPATFULL on STN

TI Treatment of pain and colorectal cancer with dipeptoids of .alpha.-substituted Trp-Phe derivatives

AB This invention relates to the treatment of pain and inhibiting the growth of colorectal cancer with dipeptoids of .alpha.-substituted Trp-Phe derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:111485 USPATFULL
TITLE: Treatment of pain and colorectal cancer with dipeptoids of .alpha.-substituted Trp-Phe derivatives
INVENTOR(S): Horwell, David C., Foxton, England
Pritchard, Martyn C., Swavesey, England
Roberts, Edward, Wood Ditton, England
Richardson, Reginald S., Haverhill, England
Aranda, Julian, Vorstetter, Germany, Federal Republic of
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5580896		19961203
APPLICATION INFO.:	US 1995-447142		19950522 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-235814, filed on 28 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-958196, filed on 7 Oct 1992, now abandoned which is a division of Ser. No. US 1990-629809, filed on 19 Dec 1990, now patented, Pat. No. US 5278316 which is a continuation-in-part of Ser. No. US 1990-545222, filed on 28 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-530811, filed on 5 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-422486,

filed on 16 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-374327, filed on 29 Jun 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 5615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 11 USPATFULL on STN
TI 1-pyrimidinylacetamide human leukocyte elastate inhibitors
AB The present invention relates to certain novel substituted ketones which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates ##STR2## useful in the synthesis of these substituted ketones processes for preparing the substituted ketones pharmaceutical compositions containing such substituted ketones and methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 95:73641 USPATFULL
TITLE: 1-pyrimidinylacetamide human leukocyte elastate inhibitors
INVENTOR(S): Bernstein, Peter R., Wallingford, PA, United States
Edwards, Philip D., Kennett Square, PA, United States
Shaw, Andrew, Kennett Square, PA, United States
Thomas, Royston M., Macclesfield, England
Veale, Chris A., Newark, DE, United States
Warner, Peter, Macclesfield, CT, United States
Wolanin, Donald J., Orange, CT, United States
PATENT ASSIGNEE(S): Zeneca Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5441960		19950815	
APPLICATION INFO.:	US 1993-44866		19930408	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-8383	19920416
	GB 1992-17367	19920814

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gupta, Yogendra N.
LEGAL REPRESENTATIVE: Browder, Monte R., Harris, Robert J., Jackson, Thomas E.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 2263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 11 USPATFULL on STN
TI N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives
AB Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives

useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:3937 USPATFULL

TITLE: N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives

INVENTOR(S): Horwell, David C., Cambridge, England
Pritchard, Martyn C., Cambridge, England
Richardson, Reginald S., Suffolk, England
Roberts, Edward, Newmarket, England
Aranda, Julian, Vorstetten, Germany, Federal Republic of

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5278316		19940111
APPLICATION INFO.:	US 1990-629809		19901219 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-545222, filed on 28 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-530811, filed on 5 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-422486, filed on 16 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-374327, filed on 29 Jun 1989, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	NZ 1990-234264	19900627

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Chang, Celia
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Figure(s); 25 Drawing Page(s)
LINE COUNT: 5378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:00:20 ON 11 SEP 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 11:00:32 ON 11 SEP 2003

L1 10 S FLASH COMPOUND
L2 189641 S FLUORESCEIN ARSENICAL HELIX BINDER COMPOUND OR FLASH
L3 4962 S L2 AND ACYLATION
L4 303 S L3 AND BETA ALANINE

L5 11 S L4 AND TAUTOMER

=> s l4 and salt
L6 276 L4 AND SALT

=> s l5 and l6
L7 11 L5 AND L6

=> d l6 ti abs ibib 1-15

L6 ANSWER 1 OF 276 USPATFULL on STN
TI Compounds which inhibit leukocyte adhesion mediated by VLA-4
AB Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

ACCESSION NUMBER: 2003:238417 USPATFULL
TITLE: Compounds which inhibit leukocyte adhesion mediated by VLA-4
INVENTOR(S): Dappen, Michael S., Redwood City, CA, UNITED STATES
Dressen, Darren B., San Mateo, CA, UNITED STATES
Grant, Francine S., San Francisco, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Robinson, Cynthia Y., Belmont, CA, UNITED STATES
Sarantakis, Dimitrios, Newtown, PA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166575	A1	20030904
APPLICATION INFO.:	US 2002-266889	A1	20021007 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-127533, filed on 31 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-112010P	19970731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 5434

L6 ANSWER 2 OF 276 USPATFULL on STN
TI Peptide nucleic acids having 2,6-diaminopurine nucleobases
AB A novel class of compounds, known as peptide nucleic acids, bind complementary DNA and RNA strands more strongly than a corresponding DNA strand, and exhibit increased sequence specificity and binding affinity. The peptide nucleic acids of the invention comprise ligands selected from a group consisting of naturally-occurring nucleobases and non-naturally-occurring nucleobases attached to a polyamide backbone. Some PNAs of the invention also contain C.sub.1-C.sub.8 alkylamine side chains.

ACCESSION NUMBER: 2003:234832 USPATFULL
TITLE: Peptide nucleic acids having 2,6-diaminopurine

nucleobases

INVENTOR(S): Buchardt, Ole, late of V.ae butted.rl.o slashed.se, DENMARK deceased
Mrs. Dorte Buchardt, United States legal representative
Egholm, Michael, Lexington, MA, United States
Nielsen, Peter Eigil, Kokkedal, DENMARK
Berg, Rolf Henrik, Kyst, DENMARK

PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6613873	B1	20030902
APPLICATION INFO.:	US 1999-337304		19990621 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-847110, filed on 1 May 1997, now abandoned Division of Ser. No. US 1996-686114, filed on 24 Jul 1996, now patented, Pat. No. US 6414112 Continuation-in-part of Ser. No. US 1993-108591, filed on 22 Nov 1993, now patented, Pat. No. US 6395474

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1991-987	19910524
	DK 1991-986	19910524
	DK 1992-510	19920415

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Woodcock Washburn LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 4342

L6 ANSWER 3 OF 276 USPATFULL on STN
TI Amino acid ester containing azole antifungals
AB The present invention concerns novel compounds of formula ##STR1##

the N-oxide forms, the pharmaceutically acceptable addition salts thereof and stereochemically isomeric forms thereof, wherein --A--B-- forms a bivalent radical of formula --N.dbd.CH-- (a), --CH.dbd.N-- (b), --CH.dbd.CH-- (c), L represents the acyl moiety of an amino acid; D is an azole containing 1,3- or 1,4-dioxolane derivative as broad-spectrum antifungals; their preparation, compositions containing them and their use as a medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:226397 USPATFULL
TITLE: Amino acid ester containing azole antifungals
INVENTOR(S): Meerpoel, Lieven, Beerse, BELGIUM
Heeres, Jan, Vosselaar, BELGIUM
Hendrickx, Robert Jozef Maria, Beerse, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158210	A1	20030821
APPLICATION INFO.:	US 2002-298038	A1	20021115 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-848989, filed on 4 May 2001, GRANTED, Pat. No. US 6512116 Division of Ser. No. US 1999-355369, filed on 26 Jul 1999, GRANTED, Pat. No. US 6262052

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1997-200374	19970211
	EP 1997-203228	19971015

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 276 USPATFULL on STN
TI Collections of compounds
AB A compound of formula (IV): O is a solid support; L is a linking group or a single bond; X' is selected from CO, NH, S, or O; A is O, S, NH, or a single bond; R.sub.2 and R.sub.3 are independently selected from: H, R, OH, OR, .dbd.O, .dbd.CH--R, .dbd.CH.sub.2, CH.sub.2--CO.sub.2R', CH.sub.2--CO.sub.2H, CH.sub.2--SO.sub.2R, O--SO.sub.2R, CO.sub.2R, COR, CN and there is optionally a double bond between C1 and C2 or C2 and C3; R.sub.6, R.sub.7, and R.sub.9 are independently selected from H, R, OH, OR, halo, nitro, amino, Me.sub.3Sn; R.sub.11 is either H or R; Q is S, O or NH; R.sub.10 is a nitrogen protecting group; and Y is a divalent group such that HY=R, and other related compounds and collections of compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:222178 USPATFULL
TITLE: Collections of compounds
INVENTOR(S): Thurston, David Edwin, University Park, UNITED KINGDOM
Howard, Philip Wilson, University Park, UNITED KINGDOM
PATENT ASSIGNEE(S): Spirogen Limited, Ryde, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6608192	B1	20030819	
	WO 2000012506		20000309	
APPLICATION INFO.:	US 2001-763768		20010226	(9)
	WO 1999-GB2836		19990827	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-18730	19980827

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Michael Best & Friedrich LLP, Frenchick, Grady J., Yager, Charlene
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 49 Drawing Page(s)
LINE COUNT: 3533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 276 USPATFULL on STN
TI Substituted oxazolidinones and their in the field of blood coagulation
AB The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR1##

processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:220319 USPATFULL
TITLE: Substituted oxazolidinones and their in the field of blood coagulation
INVENTOR(S): Straub, Alexander, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lampe, Thomas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Pohlmann, Jens, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Rohrig, Susanne, Essen, GERMANY, FEDERAL REPUBLIC OF
Perzborn, Elisabeth, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Pernerstorfer, Joseph, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003153610	A1	20030814	
APPLICATION INFO.:	US 2002-181051	A1	20020624	(10)
	WO 2000-EP12492		20001211	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19962924	19991224

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEFFREY M. GREENMAN, VICE PRESIDENT, PATENTS AND LICENSING, BAYER CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 3805
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 276 USPATFULL on STN
TI Cytostatic agents
AB This invention provides a method of inhibiting proliferation of tumor cells in a subject by administering to the subject an effective amount of ester and thioester compounds containing an N-formyl hydroxylamine group.

The compounds with which this invention is concerned thus represent a selection of a subclass from the compounds known in the art as MMP inhibitors, for a specific and previously unrecognized pharmaceutical utility in the inhibition of proliferation of rapidly dividing cells, including such tumor cells as lymphoma, leukemia, myeloma, adenocarcinoma, carcinoma, mesothelioma, teratocarcinoma, choriocarcinoma, small cell carcinoma, large cell carcinoma, melanoma, retinoblastoma, fibrosarcoma, leiomyosarcoma or endothelioma cells by a mechanism other than MMP inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:214441 USPATFULL
TITLE: Cytostatic agents
INVENTOR(S): Ayscough, Andrew Paul, Oxford, UNITED KINGDOM
Pratt, Lisa Marie, Oxford, UNITED KINGDOM
Drummond, Alan Hastings, Oxford, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003149084	A1	20030807	
APPLICATION INFO.:	US 2002-315894	A1	20021210	(10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-622154, filed on 5 Oct 2000, GRANTED, Pat. No. US 6495597

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-2968	19980213
	GB 1998-27804	19981216

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GREENBERG TRAURIG, LLP, 885 3RD AVENUE, NEW YORK, NY, 10022
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 276 USPATFULL on STN
TI Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
AB This invention relates to a compound of the formula: ##STR1##

or a pharmaceutically acceptable **salt** thereof, wherein A and R.sup.1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R.sup.2 is NH.sub.2; R.sup.3 and R.sup.4 are each hydrogen, halo, (C.sub.1-C.sub.4)alkyl optionally substituted with halo and the like; and X.sup.1 to X.sup.4 are each hydrogen, halo, hydroxy, (C.sub.1-C.sub.4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:210094 USPATFULL
TITLE: Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
INVENTOR(S): Ando, Kazuo, Aichi-Ken, JAPAN
Kawamura, Kiyoshi, Aichi, JAPAN
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6603008	B1	20030805	
APPLICATION INFO.:	US 2000-723661		20001128	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-168889P	19991203 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fan, Jane
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Liu, Lance Y.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 276 USPATFULL on STN
TI Cyclic amine phenyl beta-3 adrenergic receptor agonists
AB This invention provides compounds of Formula I having the structure ##STR1##

wherein,

R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, T, T.sup.1, T.sup.2, and X are as defined hereinbefore, or a pharmaceutically acceptable **salt** thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:207965 USPATFULL
TITLE:	Cyclic amine phenyl beta-3 adrenergic receptor agonists
INVENTOR(S):	Hu, Baihua, Nanuet, NY, UNITED STATES Sum, Fuk-Wah, Pomona, NY, UNITED STATES Malamas, Michael Sotirios, Jamison, PA, UNITED STATES
PATENT ASSIGNEE(S):	Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144326	A1	20030731
APPLICATION INFO.:	US 2002-330576	A1	20021227 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-903754, filed on 12 Jul 2001, GRANTED, Pat. No. US 6525202		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218627P	20000717 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	9789

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 276 USPATFULL on STN

TI N-alkyl-adamantyl triazinyl benzamide derivatives

AB The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I ##STR1##

and to processs for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the treatment of inflammation, osteoarthritis, rhematoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:207932 USPATFULL
TITLE:	N-alkyl-adamantyl triazinyl benzamide derivatives
INVENTOR(S):	Duplantier, Allen J., Ledyard, CT, UNITED STATES
PATENT ASSIGNEE(S):	Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144293	A1	20030731
APPLICATION INFO.:	US 2002-292886	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336892P	20011112 (60)

DOCUMENT TYPE:	Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 276 USPATFULL on STN
TI Substituted benzimidazole compounds
AB Disclosed are substituted benzimidazole compounds of formula(I): ##STR1##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X.sub.a are defined herein. The compounds of the invention are useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:207920 USPATFULL
TITLE: Substituted benzimidazole compounds
INVENTOR(S): Cywin, Charles, Bethel, CT, UNITED STATES
Lee, Jinbo, Acton, MA, UNITED STATES
Pullen, Steven S., New Milford, CT, UNITED STATES
Roth, Gregory Paul, New Milford, CT, UNITED STATES
Sarko, Christopher Ronald, New Milford, CT, UNITED STATES
Snow, Roger John, Danbury, CT, UNITED STATES
Wilson, Noel Stewart, New Milford, CT, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144281	A1	20030731	
APPLICATION INFO.:	US 2002-288362	A1	20021105	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-344636P	20011109	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 276 USPATFULL on STN
TI Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
AB This invention relates to a compound of the formula: ##STR1##

or a pharmaceutically acceptable **salt** thereof, wherein A and R.sup.1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R.sup.2 is NH.sub.2; R.sup.3 and R.sup.4 are each hydrogen, halo, (C.sub.1-C.sub.4)alkyl optionally substituted with halo and the like; and X.sup.1 to X.sup.4 are each hydrogen, halo, hydroxy, (C.sub.1-C.sub.4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for

treating or preventing inflammation or other COX-2 related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:207919 USPATFULL
TITLE:	Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
INVENTOR(S):	Ando, Kazuo, Aichi-Ken, JAPAN Kawamura, Kiyoshi, Aichi, JAPAN
PATENT ASSIGNEE(S):	PFIZER INC., NEW YORK, NY, UNITED STATES (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144280	A1	20030731	
APPLICATION INFO.:	US 2002-334329	A1	20021231	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-723661, filed on 28 Nov 2000, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-168889P	19991203 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, GARDEN CITY, NY, 11530
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1
LINE COUNT:	4884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 276 USPATFULL on STN

TI Conformationally constrained backbone cyclized peptide analogs

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha.(.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha.(.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:207825 USPATFULL
TITLE:	Conformationally constrained backbone cyclized peptide analogs
INVENTOR(S):	Gilon, Chaim, Jerusalem, ISRAEL Eren, Doron, Rehovot, ISRAEL Zeltser, Irina, Jerusalem, ISRAEL Seri-Levy, Alon, Jerusalem, ISRAEL Bitan, Gal, Jerusalem, ISRAEL Muller, Dan, Jerusalem, ISRAEL

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144186	A1	20030731	
APPLICATION INFO.:	US 2002-167723	A1	20020912	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-580905, filed on 31 May 2000, GRANTED, Pat. No. US 6407059 Division of Ser.			

No. US 1998-120237, filed on 22 Jul 1998, GRANTED, Pat. No. US 6265375 Continuation of Ser. No. US 1995-488159, filed on 7 Jun 1995, GRANTED, Pat. No. US 5811392

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1994-109943	19940608

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 3436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 276 USPATFULL on STN
TI Low molecular weight peptidomimetic growth hormone secretagogues
AB The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:201362 USPATFULL
TITLE: Low molecular weight peptidomimetic growth hormone secretagogues
INVENTOR(S): Somers, Todd C., Foster City, CA, UNITED STATES
Elias, Kathleen A., San Francisco, CA, UNITED STATES
Clark, Ross G., Pacifica, CA, UNITED STATES
McDowell, Robert S., San Francisco, CA, UNITED STATES
Stanley, Mark S., Pacifica, CA, UNITED STATES
Burnier, John P., Pacifica, CA, UNITED STATES
Rawson, Thomas E., Mountain View, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003139348	A1	20030724	
APPLICATION INFO.:	US 2002-224640	A1	20020819	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-316505, filed on 21 May 1999, ABANDONED Continuation of Ser. No. US 1998-57074, filed on 8 Apr 1998, GRANTED, Pat. No. US 6034216 Continuation of Ser. No. US 1994-340767, filed on 16 Nov 1994, GRANTED, Pat. No. US 5798337
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 4858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 276 USPATFULL on STN
TI Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
AB Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion

mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:195063 USPATFULL
TITLE: Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
INVENTOR(S): Grant, Francine S., Milpitas, CA, UNITED STATES
Johnson, Bradley S., San Francisco, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Thorsett, Eugene D., Half Moon Bay, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134874	A1	20030717
APPLICATION INFO.:	US 2002-243731	A1	20020916 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-489157, filed on 21 Jan 2000, GRANTED, Pat. No. US 6465513		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-116735P	19990122 (60)
	US 1999-117743P	19990129 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alaxandria, VA, 22313-1404
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3988
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 276 USPATFULL on STN
TI 3,3-disubstituted-oxindole derivatives useful as anticancer agents
AB The present invention relates to compounds of formula 1 ##STR1##

and to pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein n is 0 or 1 and R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment, and to methods of preparing compounds of formula 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:176420 USPATFULL
TITLE: 3,3-disubstituted-oxindole derivatives useful as anticancer agents
INVENTOR(S): Lyssikatos, Joseph Peter, Gales Ferry, CT, United States
Yang, Bingwei Vera, Waterford, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6586447	B1	20030701

APPLICATION INFO.:	US 2000-539930	20000331 (9)
	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127340P	19990401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Huang, Evelyn Mei	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Banerjee, Krishna G.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1942	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.